Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable ...
ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.
Propensity-matched analyses showed smokers had significantly higher risk across all studied ocular outcomes over 10 years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results